Attached files
| file | filename |
|---|---|
| 10-K - FORM 10-K - PLx Pharma Inc. | v456656_10k.htm |
| EX-32.2 - EXHIBIT 32.2 - PLx Pharma Inc. | v456656_ex32-2.htm |
| EX-32.1 - EXHIBIT 32.1 - PLx Pharma Inc. | v456656_ex32-1.htm |
| EX-31.2 - EXHIBIT 31.2 - PLx Pharma Inc. | v456656_ex31-2.htm |
| EX-31.1 - EXHIBIT 31.1 - PLx Pharma Inc. | v456656_ex31-1.htm |
| EX-3.3 - EXHIBIT 3.3 - PLx Pharma Inc. | v456656_ex3-3.htm |
| EX-3.2 - EXHIBIT 3.2 - PLx Pharma Inc. | v456656_ex3-2.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-204830 on Form S-3 and Registration Statements No. 333-196824 and 333-212421 on Form S-8 of Dipexium Pharmaceuticals, Inc. of our report, dated January 19, 2017, on our audits of the consolidated financial statements of Dipexium Pharmaceuticals, Inc. as of December 31, 2016 and 2015 and for each of the years in the two-year period ended December 31, 2016, which report is included in the Annual Report on Form 10-K of Dipexium Pharmaceuticals, Inc. for the year ended December 31, 2016.
/s/ CohnReznick LLP
Roseland, New Jersey
January 19, 2017